Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.60 |
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283775 | 1.00 | ERN1 (0.60) | ERN1KMOPDK2HDAC8MEN1 | |
| Hydrochloric Acid SCHEMBL28646857 | 0.98 | ERN1 (0.59) | ERN1KMOPDK2HDAC8MEN1 | |
| Trifluoroacetic Acid SCHEMBL5067780 | 0.90 | PDK2 (0.57) | ERN1KMOPDK2HDAC8MEN1 | |
| SCHEMBL27876786 | 0.90 | SMN1; SMN2 (0.55) | ERN1KMOPDK2HDAC8MEN1 | |
| SCHEMBL12168605 | 0.90 | ERN1 (0.58) | ERN1KMOPDK2LMNA | |
| SCHEMBL18311613 | 0.87 | ERN1 (0.64) | ERN1PDK2MEN1KMT2AHSD17B2 | |
| SCHEMBL17795214 | 0.87 | ERN1 (0.60) | ERN1KMOPDK2CYP3A4MAP4K1 | |
| SCHEMBL28022357 | 0.85 | KMO (0.56) | ERN1KMOHDAC8MEN1KMT2A | |
| SCHEMBL12472078 | 0.84 | ERN1 (0.56) | ERN1PDK2CYP3A4MAP4K1HSD17B2 | |
| SCHEMBL12469445 | 0.84 | ERN1 (0.59) | ERN1PDK2CYP3A4MAP4K1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117255792-A | Heteroaryl derivatives, process for preparing the same and pharmaceutical compositions comprising the same as active ingredient | 沃若诺伊公司 | 2023-12-19 | — | — | CN | claimed |
| CN-115427409-A | Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2022-12-02 | — | — | CN | claimed |
| CN-111132961-A | Bisaryloxy derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | claimed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | claimed |
| EP-2049118-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | claimed |
| CN-117255792-A | Heteroaryl derivatives, process for preparing the same and pharmaceutical compositions comprising the same as active ingredient | 沃若诺伊公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-115776890-A | TRPV4 inhibitors as therapeutic agents for eye diseases | 拉夸里亚创药株式会社 | 2023-03-10 | — | — | CN | disclosed |
| CN-115427409-A | Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021065893-A1 | TETRALIN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | 国立大学法人 筑波大学 | 2021-04-08 | — | — | WO | disclosed |
| WO-2021061929-A1 | BICYCLIC CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | Nirogy Therapeutics, Inc. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-111132961-A | Bisaryloxy derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| EP-3154979-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | Pfizer Limited (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| EP-2035401-B1 | ARYL- AND HETEROARYL-ETHYL-ACYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2011-02-23 | — | — | EP | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| EP-2049118-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | ERN1 3541/4885KMO 1635/4885PDK2 1229/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ERN1 3541/4885KMO 1635/4885PDK2 1229/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ERN1 3541/4885KMO 1635/4885PDK2 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.